Drawing for VITALANT V

USPTO serial 87918159

VITALANT V

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
BLAIR, JASON
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with VITALANT V?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Timothy D. Fontes

TIMOTHY D. FONTES POLSINELLI PCONE EAST WASHINGTON, SUITE 1200PHOENIX, AZ 85004UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
035Inventory management in the field of biologic and specialty pharmaceutical products in the nature of therapeutic plasma-derivatives and recombinant coagulation products provided to hospitals, clinics, home care companies, hemophilia and thrombosis centers, and physician offices; promoting public awareness of the need for blood donors, namely, public awareness about blood products and community blood bank centers; arranging procurement of goods for others in the field of human bone, tissue, and organs for purposes of transplantation; and distributorship services in the field of human blood and blood products, therapeutic plasma-derivatives and recombinant coagulation productsACTIVE—
036Charitable fundraising services in the field of human blood and blood products to support blood bank operations and research in the field of transfusion medicineACTIVE—
039Storage of human bone, tissue, and organs for purposes of transplantationACTIVE—
040Processing of human bone, tissue, and organs for purposes of transplantationACTIVE—
041Educational services, namely, providing educational materials to the general public and health care professionals about blood donation and transfusion; providing training and continuing professional education courses in the field of health, safety, medicine, immunology, blood banking, transfusion and human resources and business management in the transfusion medicine and blood banking laboratory fieldsACTIVE—
042Laboratory, clinical and translational research in the field of transfusion medicine, and infectious disease; blood analysis services; medical blood laboratory services; medical research in the field of blood; and providing quality assurance services in the field of blood and blood productsACTIVE—
044Blood bank services, namely, collection, supply, preservation, distribution, and coordination of human blood and blood products; organ and tissue bank services; medical testing of blood; blood bank services, namely, processing of bloodACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Dec 23, 2019MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 23, 2019ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 13, 2019ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
May 22, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
May 20, 2019EX1GSOU EXTENSION 1 GRANTED—
May 20, 2019EXT1SOU EXTENSION 1 FILED—
May 20, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 20, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 25, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 25, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 5, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 21, 2018ALIEASSIGNED TO LIE—
Aug 2, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 1, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 19, 2018GEANNOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Jul 19, 2018GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Jul 19, 2018EPENCOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY—
Jul 19, 2018CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
Jul 12, 2018DOCKASSIGNED TO EXAMINER—
Jun 5, 2018DOCKASSIGNED TO EXAMINER—
May 20, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 15, 2018NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance